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bjectives The aim of this study was to determine which drug-eluting stent (DES) is preferable for
he treatment of ST-segment elevation myocardial infarction (STEMI) and to elucidate the impact of
iabetes mellitus on the outcome of each DES.
ackground Recent studies have shown the beneﬁt of DES in patients with STEMI. Diabetes melli-
us might differentially affect outcomes of each DES.
ethods We analyzed the large-scale, prospective, observational KAMIR (Korea Acute Myocardial
nfarction Registry) study, which enrolled 4,416 STEMI patients (26% with diabetes) treated with
aclitaxel-eluting stent (PES) or sirolimus-eluting stent (SES). Primary outcome was major adverse
ardiac event (MACE), deﬁned as a composite of mortality, nonfatal myocardial infarction, and target
esion revascularization (TLR).
esults In the overall population, the MACE rate at 1 year was signiﬁcantly higher in the PES than
he SES group (11.6% vs. 8.6%, p  0.014), which was mainly due to increased TLR (3.7% vs. 1.8%,
 0.001). In the diabetic subgroup, however, the MACE rate was not signiﬁcantly different be-
ween PES and SES (14.5% vs. 12.3%, p  0.217), in contrast to the nondiabetic subgroup, where
ES was inferior to SES as in the overall population. Matching by propensity-score did not signiﬁ-
antly alter these results. For TLR, there was interaction between the type of stents and diabetes
ellitus (unadjusted: p  0.052; after propensity-score matching: p  0.035).
onclusions The PES was inferior to the SES in the overall population, with regard to the occur-
ence of MACE and TLR. However, subgroup analysis for diabetic subjects showed no differences in
linical outcomes between PES and SES. These results suggest that diabetes differentially affects the
utcome of ﬁrst-generation DES. (J Am Coll Cardiol Intv 2010;3:498–506) © 2010 by the American
ollege of Cardiology Foundation
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499he presence of diabetes mellitus is 1 of the compelling
ndications to use drug-eluting stents (DES) over bare-metal
tents during elective percutaneous coronary intervention (PCI)
1,2). Recently, data from randomized trials (3,4) and the large
assachusetts PCI registry (5) have shown the benefit and safety
f DES even in patients with ST-segment elevation myocardial
nfarction (STEMI), which might lead to a significantly increased
enetration of DES use in such patients. However, data compar-
ng different DES in patients with STEMI are scarce, and
urthermore, the impact of diabetes in the performance of each
ES in these high-risk patients is mostly unknown.
Therefore, we sought to determine which DES is pref-
rable for the treatment of STEMI in diabetic patients and
o elucidate the impact of diabetes mellitus on outcome of
ach DES by analyzing the largest acute myocardial infarc-
ion (AMI) database registry in Korea.
ethods
tudy population and KAMIR (Korean Acute Myocardial
nfarction Registry). In Korea, a nationwide effort was
aunched in 2005 to collect data from patients with AMI
dmitted to major cardiac centers capable of primary PCI,
hich was named the KAMIR. It is a large-scale, multi-
enter, Internet-based AMI registry, where 49 institutions
re actively enrolling patients. It is the largest AMI registry
n Korea and, to the best of our knowledge, one of the
argest in the world. Since November 2005 to January 2008,
4,049 patients with AMI have been enrolled in the
AMIR. The general characteristics of KAMIR have been
escribed elsewhere (6), and the study protocol was ap-
roved by the ethics committee at each participating
nstitution.
For the present study, patients who underwent PCI with
aclitaxel-eluting stent (PES) or sirolimus-eluting stent
SES) for STEMI were selected, which comprised 4,816 of
he 14,049 total registered patients. With exclusion of 400
atients lost to follow-up within 1 month, a total of 4,416
atients—of which 1,137 (26%) had diabetes mellitus—
ere finally analyzed (Fig. 1). The proportions of patients
eceiving each DES at specified time periods were not
ignificantly different (Online Fig. 1).
tudy deﬁnitions. The presence of diabetes mellitus and
ype of diabetes treatment (insulin or oral antidiabetic
gents) was documented through self-reporting by the
atient. The level of glycosylated hemoglobin (HbA1c)
uring hospital stay and the information on the diabetic
icrovascular complications (nephropathy, retinopathy, or
europathy) were additionally collected at the time of the
Chonnam National University Hospital, Gwangju, Korea; and the ¶¶¶Medical Res
ollege of Medicine, Seoul, Korea. This work was supported by the Innovative Resera
isease (0412-CR02-0704-0001). The first 3 authors contributed equally to this woanuscript received February 1, 2010, accepted February 5, 2010.nalysis, with retrospective review of medical records. Data
n other cardiovascular risk factors such as hypertension,
moking, and prior ischemic heart disease were also re-
orted by the patients themselves, except dyslipidemia,
hich was defined as a composite of self-reported history,
rior statin usage, and fasting cholesterol 200 mg/dl.
ngiographic parameters such as Thrombolysis In Myocar-
ial Infarction (TIMI) flow grade or American College of
ardiology/American Heart Association lesion type were
ssessed by the operator. Successful procedure was defined
s 20% residual stenosis after procedure in this study.
Major adverse cardiac event (MACE) was defined as a
omposite of mortality from any cause, nonfatal myocardial
nfarction, and target lesion revas-
ularization (TLR). Myocardial
nfarction was defined as the pres-
nce of at least 2 of the following
conditions: 1) ischemic symp-
oms; 2) elevation of cardiac
arkers at least twice the upper
imit of normal; or 3) new ST-
egment elevation. The TLR was
efined as a repeated intervention
surgical or percutaneous) result-
ng from restenosis or re-occlusion
ithin the stent or in the adjacent
-mm segments.
CI and follow-up. Coronary in-
erventions were performed ac-
ording to current standard pro-
edural guidelines. The choice of
ES or SES was left to the
perator’s discretion. Aspirin and
lopidogrel (loading dose, 300
g, or 600 mg) were prescribed
efore or during the coronary in-
ervention. After the procedure,
lopidogrel was prescribed for at
east 6 months, and aspirin was
ontinued indefinitely. All pa-
ients were scheduled to be fol-
owed clinically at 1 month, 6 months, and 1 year after the
ndex procedure. Routine angiographic follow-up for asymp-
omatic patients was not mandatory. Primary outcome in this
tudy was cumulative MACE rate within 1 year after PCI.
tatistical analysis. Student t test and chi-square (or Fisher’s
xact) test were used to compare means and proportion of
aseline clinical and angiographic characteristics between 2
tent groups. After checking for the violation of propor-
ollaborating Center, Department of Preventive Medicine, Seoul National University
titute for Cell Therapy (IRICT) and the Clinical Research Center for Ischemic Heart
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CI  confidence interval
DES  drug-eluting stent(s)
HbA1c  glycosylated
hemoglobin
HR  hazard ratio
MACE  major adverse
cardiac event
mTOR  mammalian target
of rapamycin
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
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500ional hazard assumption, the Cox proportional hazard
odel was used to estimate the hazard ratio (HR) and 95%
onfidence interval (CI) for clinical outcomes between 2
tent groups in crude study population. The p value for
nteraction between the stent type and the presence of
iabetes mellitus was calculated by testing significance with
likelihood ratio test in the Cox regression model, includ-
ng an interaction term.
To address potential sources of bias and confounding in
his observational study, rigorous adjustment was conducted
y the use of propensity analysis (7,8). Propensity score for
tent choice was computed by nonparsimonious logistic
egression model (c-statistics  0.640). Except outcome
ariables and prescribed medications after stenting, baseline
linical and angiographic features listed in Table 1 were
ncorporated for this model. Morbidity of diabetes mellitus
as also excluded from this calculation, because it was an
nterested independent variable. We confirmed the model
eliability with goodness-of-fit test (p  0.101) and then
erformed 1:1 match iteration by propensity score from
nitial 8 to 1 digit. Baseline covariates were compared again
n this matched population with paired t test or McNemar
est (or marginal homeogeneity test). With the robust
andwich covariance matrix estimation, the HR (95% CIs)
Figure 1. Study Population Diagram
AMI  acute myocardial infarction; BMS  bare-metal stent(s); DES  drug-elu
non–ST-segment elevation myocardial infarction; PCI  percutaneous coronary
STEMI  ST-segment elevation myocardial infarction.f clinical outcomes between PES and SES group were rstimated with the Cox proportional hazard model, adjusted
or covariates as follows: lesion type B2/C, stent length, stent
iameter, number of implanted stents that were well-known
redictors for revascularization of DES (9), post-procedural
IMI flow grade 3, achievement of procedural success, and
rescribed medication at the time of discharge. The HbA1c
evel, diabetic microvascular complication, and insulin require-
ent were additionally adjusted for the diabetic subgroup.
azard ratio of recurrent myocardial infarction was estimated
ithout adjustment for these covariates, because it interfered
ith the development of reliable regression model. All of these
tatistical analyses were performed with SAS version 9.1.3
SAS Institute, Cary, North Carolina), and p value0.05 was
onsidered as significant.
esults
aseline characteristics of crude study population. Baseline
linical and angiographic characteristics of crude study
opulation are presented in Table 1. The SES group was
lightly younger, had a higher incidence of diabetes mellitus,
nd underwent stent implantation more frequently as pri-
ary angioplasty. With respect to angiographic features, the
eft anterior descending artery was more often the infarct-
tent(s); KAMIR  Korean Acute Myocardial Infarction Registry; NSTEMI 
vention; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s);ting s
interelated artery for the SES group, and B2/C lesions defined by
t
P
s
m
p
C
f
s
T
a
m
m
r
n
a
d
b
i
w
S
B
i
t
t
d
f
S
7
f
C
P
n
(
n
i
0
1
e
a
m
0
A
C
d
e
t
a
f
i
s
C
o
p
i
sirolimus-eluting stent(s); TIMI Thrombolysis In Myocardial Infarction.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 5 , 2 0 1 0 Cho et al.
MA Y 2 0 1 0 : 4 9 8 – 5 0 6 DES for Diabetic STEMI Patient
501he American College of Cardiology was more frequent in the
ES group. The SES group tended to use longer stents with
maller diameter, whereas the PES group tended to implant
ore stents during the index procedure. The use of glyco-
rotein IIb/IIIa inhibitor was higher in the PES group.
linical outcomes of crude study population up to 1-year
ollow-up. With median follow-up of 365 days in crude
tudy population, a cumulative total of 396 events occurred.
he estimated 1-year MACE rate was 9.5%. Unadjusted
nalysis revealed that the PES usage as well as diabetes
ellitus was associated with increased MACE. Diabetes
ellitus definitely augmented the risk (p  0.001), with
egard to mortality from any cause, but the type of DES was
ot a significant risk factor (p 0.543). The PES usage was
ssociated with higher TLR rate (p  0.001), whereas
iabetes mellitus increased the risk for TLR only with
orderline statistical significance (p  0.092) (Fig. 2). The
nteraction between diabetes mellitus and the type of DES
as noteworthy only for TLR (p  0.052).
ubgroup analysis in diabetic and nondiabetic population.
ASELINE CHARACTERISTICS. Given the results described
n the preceding text, we performed subgroup analysis for
he diabetic and nondiabetic populations. Baseline charac-
eristics of each population are presented in Online Table 1. In
iabetic patients, diabetic microvascular disease was more
requent and the level of HbA1c tended to be higher in the
ES group. In the nondiabetic population, which constituted
4% of the total study population, clinical and angiographic
eatures followed the trend of the overall population.
LINICAL OUTCOMES OF DIABETIC AND NONDIABETIC
OPULATION. In diabetic patients with STEMI, there was
o significant difference in MACE (p  0.217) or TLR
p  0.448) between the 2 stent groups. However, in the
ondiabetic population, PES use was associated with higher
ncidence of MACE (HR: 1.36; 95% CI: 1.06 to 1.74, p 
.016), mainly due to increased TLR (HR: 3.21, 95% CI:
.83 to 5.63, p  0.001). The 2 groups did not differ from
ach other, with respect to the hard end points such as
ll-cause mortality, regardless of the presence of diabetes
ellitus (for diabetic, p  0.300; for nondiabetic, p 
.820) (Fig. 3).
nalysis in patients matched for propensity score. BASELINE
HARACTERISTICS. We performed propensity analysis as
escribed in the Methods section, and 1,451 patients from
ach stent group were matched for propensity score. Of
hese, 667 (23%) were diabetic; other baseline characteristics
re listed in Table 2. All baseline clinical and angiographic
eatures became comparable after propensity score match-
ng. Baseline characteristics of the diabetic and nondiabetic
ubpopulations are provided in Online Table 2.
LINICAL OUTCOMES UP TO 1 YEAR. With median follow-up
f 368 days, a total of 212 MACE occurred in the matched
opulation, and the estimated 1-year MACE rate was 9.4%Table 1. Baseline Characteristics of Patients in Crude Population
Characteristics
Total Patients
PES
(n  1,882)
SES
(n  2,534)
p
Value
Age, yrs 63 12 62 12 0.01
Male 1,407 (75) 1,885 (74) 0.77
Initial hypotension 225 (12) 315 (13) 0.62
LVEF 51 12 50 11 0.33
Symptom to door time 12 h 1,506 (81) 2,005 (80) 0.58
Smoking 927 (49) 1,219 (48) 0.45
Hypertension 843 (45) 1,140 (45) 0.90
Dyslipidemia 663 (35) 945 (37) 0.16
Diabetes mellitus 443 (24) 694 (27) 0.004
Previous myocardial infarction 49 (3) 52 (2) 0.23
Previous PCI 52 (3) 95 (4) 0.07
Previous CABG 9 (0.5) 9 (0.4) 0.53
Malignancy 19 (1) 30 (1) 0.58
Primary PCI 1,440 (77) 2,044 (81) 0.001
Glucose, mg/dl 173 81 177 78 0.08
Creatinine, mg/dl 1.1 1.1 1.1 1.0 0.38
Creatine kinase-MB fraction, IU/l 200 301 203 283 0.72
Infarct-related coronary vessel 0.001
LM 22 (1) 36 (1)
LAD 924 (49) 1,446 (57)
LCX 199 (11) 219 (9)
RCA 731 (39) 828 (33)
Number of diseased vessels 0.94
1 852 (46) 1,141 (45)
2 581 (31) 790 (32)
3 439 (24) 580 (23)
ACC/AHA lesion type B2/C 1,488 (82) 1,785 (76) 0.001
Pre-procedural TIMI ﬂow grade 3 381 (21) 545 (22) 0.28
Glycoprotein IIb/IIIa inhibitor 403 (21) 373 (15) 0.001
Stent length, mm 25 6 26 6 0.001
Stent diameter, mm 3.2 0.4 3.1 0.4 0.001
Number of implanted stents 1.6 0.9 1.4 0.7 0.001
Post-procedural TIMI ﬂow grade 3 1,704 (94) 2,273 (94) 0.59
Successful procedure 1,836 (98) 2,459 (98) 0.46
Discharge medication
Aspirin 1,852 (99) 2,499 (99) 0.56
Clopidogrel 1,845 (98) 2,487 (98) 0.81
Beta-blocker 1,345 (72) 1,802 (71) 0.79
ACEi or ARB 1,528 (81) 2,031 (80) 0.38
Statin 1,523 (81) 1,999 (79) 0.09
Duration of F/U days, median (IQR) 369 (201–409) 366 (196–418) 0.74
Angiography F/U 645 (34) 859 (34) 0.80
Valuesgivenaspercentageunless otherwise indicated.Datamightnot sumto total due tomissed
values.
ACC/AHAAmericanCollegeof Cardiology/AmericanHeart Association; ACEi angiotensin-
converting enzyme inhibitor; ARB  angiotensin receptor blocker; CABG  coronary artery
bypass graft; F/U follow-up; IQR interquartile range; LAD left anterior descending; LCX
left circumflex; LM  left main; LVEF  left ventricular ejection fraction; PCI  percutaneous
coronary angioplasty; PES  paclitaxel-eluting stent(s); RCA  right coronary artery; SES n the PES group and 6.5% in the SES group (p 0.007). The
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502ox proportional hazard regression model for this matched
opulation revealed results similar to the crude study popula-
ion with more significant interaction p value between the
Figure 2. Cumulative Incidences of MACE, All-Cause Mortality, and TLR in
Cumulative incidences of major adverse cardiac events (MACE) (A, D), all-cause
population: comparison of PES versus SES or diabetes mellitus (DM) versus no
Diabetes mellitus augmented the risk for death, and PES usage increased the
Figure 3. Clinical Outcomes of Diabetic and Nondiabetic Population
Note that the inferiority of PES to SES regarding MACE and TLR rates in the no
signiﬁcant interaction between DM and the type of DES for TLR (p  0.052). PY  pES type and diabetes mellitus (Figs. 4 and 5). The estimated
-year TLR rates for each group were as follows: 4.1% for
ES and 4.4% for SES group in diabetic patients (p 
Study Population
ality (B, E), and target lesion revascularization (TLR) (C, F) in crude study
patients. The PES usage as well as DM was associated with increased MACE.
te. HR  hazard ratio; other abbreviations as in Figure 1.
etic population disappears in the diabetic population. There is borderlineCrude
mort
n-DMndiab
atient-year; other abbreviations as in Figures 1 and 2.
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503.767); and 4.0% for PES and 1.5% for SES group in
ondiabetic patients (p  0.003). And the incidence curve
f TLR in the SES group of the nondiabetic population was
Table 2. Baseline Characteristics of Patients Matched for
Propensity Score
Characteristics
Total Patients
PES
(n  1,451)
SES
(n  1,451) p Value
Age, yrs 62 12 63 12 0.781
Male 1,094 (75) 1,095 (76) 1.000
Initial hypotension 162 (11) 163 (11) 1.000
LVEF 50 12 50 11 0.702
Symptom to door time 12 h 1,173 (81) 1,157 (80) 0.478
Smoking 728 (50) 735 (71) 0.824
Hypertension 634 (44) 643 (44) 0.761
Dyslipidemia 523 (36) 538 (37) 0.591
Diabetes mellitus 338 (23) 329 (23) 0.725
Previous myocardial infarction 35 (2) 33 (2) 0.901
Previous PCI 40 (3) 54 (4) 0.175
Previous CABG 8 (0.6) 6 (0.4) 0.791
Malignancy 15 (1) 15 (1) 1.000
Primary PCI 1,101 (76) 1,107 (76) 0.819
Glucose, mg/dl 170 74 168 68 0.451
Creatinine, mg/dl 1.1 0.9 1.1 1.2 0.608
Creatine kinase-MB fraction, IU/l 205 323 199 305 0.589
Infarct-related coronary vessel 0.489
LM 15 (1) 10 (1)
LAD 760 (52) 753 (52)
LCX 150 (10) 145 (10)
RCA 526 (36) 543 (37)
Number of diseased vessels 0.797
1 693 (48) 689 (48)
2 446 (31) 443 (31)
3 312 (22) 319 (22)
ACC/AHA lesion type B2/C 1,172 (81) 1,164 (80) 0.739
Pre-procedural TIMI ﬂow grade 3 309 (22) 339 (24) 0.215
Glycoprotein IIb/IIIa inhibitor 283 (20) 268 (19) 0.476
Stent length, mm 25 6 26 6 0.485
Stent diameter, mm 3.2 0.4 3.2 0.3 0.955
Number of implanted stents 1.5 0.8 1.5 0.8 0.895
Post-procedural TIMI ﬂow grade 3 1,367 (95) 1,367 (95) 0.797
Successful procedure 1,426 (99) 1,414 (98) 0.203
Discharge medication
Aspirin 1,433 (99) 1,435 (99) 0.864
Clopidogrel 1,429 (99) 1,428 (98) 1.000
Beta-blocker 1,059 (73) 1,051 (72) 0.775
ACEi or ARB 1,201 (83) 1,197 (83) 0.886
Statin 1,195 (82) 1,188 (82) 0.776
Duration of F/U days, median (IQR) 372 (224–412) 368 (207–413) 0.880
Angiography F/U 532 (37) 545 (38) 0.646
Values given as percentage unless otherwise indicated.
Abbreviations as in Table 1.ocated in the lowest area from index procedure to final tollow-up time (Fig. 6). The risk for the composite of
ll-cause mortality was not significantly different between 2
tent groups, with regard to the hard end point (p  0.875
or diabetic, p  0.259 for nondiabetic).
iscussion
he current study represents the largest multicenter com-
arison of PES and SES implantation for patients with
TEMI in Korea. The main finding of this study was that
n the overall and nondiabetic population SES showed
ower risk of MACE than PES up to 1 year, mainly due to
reduction in TLR. However, among diabetic patients
here was no significant difference, suggesting that diabetes
ight differentially affect the outcomes of PES and SES in
atients with STEMI. This was statistically tested by
nteraction p value, which revealed borderline significance.
ropensity analysis made this implication more convincing,
ith evident statistical significance.
The PES group showed, with respect to the hard end
oint represented by all-cause mortality in this study,
lightly more events than the SES group, which was not
ignificant. Regarding the nonfatal myocardial infarction,
he incidence was too low to make any solid comparison
etween the 2 DES groups.
omparison with previous studies. The estimated 1-year
ACE rates for the overall population of this study were
1.6% in PES and 8.6% in SES group. These were
omparable to the results from the AMI subgroup of the
uropean RESEARCH/T-SEARCH (Rapamycin-
luting Stent Evaluated at Rotterdam Cardiology Hospital/
axus-Stent Evaluated At Rotterdam Cardiology Hospital)
egistry, which reported 1-year MACE as 15.4% in PES
nd 9.7% in SES group (10). After matching for propensity
core the estimated 1-year MACE rates became 9.4% in
ES and 6.5% in SES group, which were also similar to the
esults of randomized trials conducted for AMI patients
uch as the PASSION (Paclitaxel-Eluting Stent Versus
onventional Stent in ST-Segment Elevation Myocardial
nfarction) (8.8% in PES group), TYPHOON (Trial to
ssess the Use of the Cypher Stent in Acute Myocardial
nfarction Treated with Angioplasty) (7.3% in SES group)
r SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal
tent in Acute Myocardial Infarction) trials (6.8% in SES
roup). Comparing the baseline characteristics of the cur-
ent study with these randomized trials also suggested that
he study populations were not different for the most part
3,4,11).
There had been many studies about relative efficacy of
ES versus SES (12,13), and recent collaborative network
eta-analysis comprising 40 randomized trials concludedhat the patients receiving SES had a lower risk for repeat
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504evascularization compared with patients receiving PES
14). Only a few studies directly compared SES and PES
reviously, with regard to the patients with AMI, mostly
eing limited in size (10,15). Our group previously reported
hat SES, compared to PES, was associated with remark-
bly lower 1-year MACE rate in the AMI subgroup of the
orean VERITAS (VERIfy Thrombosis risk ASsessment)
egistry (16), and the current study again confirmed the
uperior efficacy of SES over PES in STEMI patients.
Meanwhile, superiority of SES was not apparent in
atients with diabetes mellitus. Although Dibra et al. (17)
eported that SES had lower late loss than PES in diabetic
atients, several registry data showed conflicting results
Figure 4. Cumulative Incidences of MACE, All-Cause Mortality, and TLR in
Cumulative incidences of MACE (A), all-cause mortality (B), and TLR (C) in pati
usage was associated with increased MACE and TLR, as in the crude study pop
Figure 5. Clinical Outcomes of Patients Matched for Propensity Score
The analysis for the propensity-score matched population shows results simila
DES type and DM for target lesion revascularization is signiﬁcant. Abbreviations as in15,18,19). The most recently reported meta-analysis of the
iabetic patients concluded that there were no significant
ifferences in clinical outcomes between SES and PES (20).
e also addressed comparability between 2 DES in diabetic
TEMI patients in this study, which implied extrapolation
f the results from the overall diabetic population to the
iabetic STEMI population.
nsights into the possible mechanisms. Each drug eluted by
ES has its specific site of action to suppress proliferation
nd migration of vascular smooth muscle cells, thus reduc-
ng neointimal hyperplasia. It is microtubule for paclitaxel
nd mammalian target of rapamycin (mTOR) for sirolimus
21,22).
nts Matched for Propensity Score
atched for propensity score: comparison between PES and SES. The PES
n. Abbreviations as in Figure 2.
ose of the crude study population. Note that the interaction between thePatie
ents mr to th
Figures 1 and 3.
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505There are 2 possible explanations for the different re-
ponse to diabetes mellitus according to the stent type. One
s that phosphatidylinositol-3-kinase/AKT/mTOR signal
xis activated via insulin receptor substrate 1 is already
eakened by the characteristic insulin resistance of type II
iabetes (23), and this attenuates the effect of sirolimus,
hich blocks mTOR. The other is that mTOR blockade by
irolimus induces AKT activation paradoxically and en-
ances migration of vascular smooth muscle cells via signal
athways bypassing mTOR, like FOXO1 or p27. Patterson
t al. (24) reported that this paradoxical AKT activation
ecomes even more striking under insulin resistance, which
mphasizes the attenuated efficacy of sirolimus in diabetic
atients.
Theoretically, reduced efficacy of sirolimus in the diabetic
ondition could be a class effect of “-limus” drugs. In fact,
here was a positive interaction between diabetes and stent
ype for MACE in a recent randomized trial comparing
verolimus-eluting stent versus PES (25), supporting the
forementioned explanation.
linical implications. There might be differences in the
elative efficacy between PES and SES according to the
pecific subgroups. And for the patients who have 2 of
he major high-risk factors, diabetes and STEMI, it had not
een fully evaluated due to the difficulty in enrollment of
ufficient patients to test the difference in clinical outcomes
etween 2 stents. Therefore, the current study analyzing the
arge AMI registry, KAMIR, has important implications as
he first study that compared PES with SES for the
Figure 6. Cumulative TLR Rates of Propensity Score Matched Population
up to 1-Year Follow-Up
The incidence curve of TLR in the nondiabetic SES group was located in
the lowest area from index procedure to ﬁnal follow-up time. Abbreviations
as in Figures 1 and 2.reatment of diabetic STEMI patients in the real-world oetting with adequate power. In addition, it adds evidence to
revious observations on the possible interaction between
iabetes and the type of DES.
Furthermore, it is noteworthy that theoretically the im-
act of diabetes on TLR of SES could be extrapolated to
ewer “-limus”-coated stents: zotarolimus-eluting and
verolimus-eluting stents. Thus, the current study empha-
izes dedicated analysis in a diabetic subgroup when verify-
ng the efficacy of newer “-limus”-eluting stents, because it
ight differ from the results of the overall population.
tudy limitations. This is a nonrandomized registry-based
tudy. Although we conducted propensity analysis to over-
ome this limitation, there still remains the possibility of
ias from unmeasured variables.
Another limitation is the lack of long-term follow-up
ata. Our recent data revealed that the late “catch-up”
henomenon was more prominent in SES than in PES
26). Moreover, the SIRTAX (Sirolimus-Eluting Stent
ompared With Paclitaxel-Eluting Stent for Coronary
evascularization) trial at 5 years showed no difference in
linical outcomes between SES and PES, in contrast to the
uperior efficacy of SES at 1-year follow-up (27). Thus,
urther observation is needed to draw more definite conclu-
ions on the long-term clinical outcomes. Also the KAMIR
acks quantitative coronary angiography data. Instead, stent
iameter and length, which reflect vessel diameter and
esion length, were adjusted.
Incomplete data on stent thrombosis is another limita-
ion. At the beginning of the KAMIR investigation, occur-
ence of stent thrombosis was not measured. With increas-
ng concerns about DES thrombosis (28,29), the KAMIR
atabase was updated to include this item in November
006. Available data from 1,812 STEMI patients indicated
hat PES did not differ from SES with regard to the risk for
tent thrombosis within 1 year (1.7% vs. 1.4%, p  0.650).
mong 1,506 patients whose data on antiplatelet drug
rescription during follow-up was fully available, 103 pa-
ients ceased clopidogrel before 6 months from index
rocedure (6.7% in PES vs. 6.9% in the SES group; p 
.641), and instead, cilostazol or ticlopidine was prescribed
or 36 patients.
Although angiographic follow-up was not mandatory,
ore than 30% of the study population underwent
ollow-up angiography. We cannot absolutely rule out the
ossibility of bias caused by “oculo-stenotic reflex,” which
ould have influenced unfavorably on the outcomes of the
ES group, due to more late-luminal loss.
Finally, because almost all patients enrolled in the KAMIR
ere Korean, it might be difficult to generalize the results of
he present study to other ethnic groups. However, because
ata from oriental patients were relatively insufficient to date,
ur data are at least a good supplementation.
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506onclusions
n the overall and nondiabetic Korean STEMI population,
ES was inferior to SES in terms of MACE, mostly due to
higher rate of TLR up to 1 year after PCI. However, in a
iabetic Korean STEMI population, PES was as good as
ES with regard to mortality, recurrent myocardial infarc-
ion, TLR, and a composite of these. Our data suggest that
iabetes mellitus might differentially affect the risk of TLR
ccording to the type of DES.
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